drugset / Trial / NCT04602845

Remimazolam Tosilate Sedation and Midazolam Sedation in Dental Patients

NCT04602845

Phase 4 Completed 81 enrolled Peking University
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Remimazolam Tosilate is a new short-acting benzodiazepines used in sedation. It has the advantages of rapid metabolism, quick recovery without injection pain. This study aims to compared with Midazolam, study whether Remimazolam Tosilate can achieve the same sedation effect with lower side effects on sedation maintenance period, During the recovery period of anesthesia, can Remimazolam Tosilatebe more stable and rapid.

Timeline

Start
2021-04-01
Primary completion
2021-06-30
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Midazolam Small molecule 2.5 mg Intravenous
Subject Remimazolam Small molecule 3 mg Intravenous
Background Fentanyl Other / unclassified 50 ug Intravenous
Background Flurbiprofen Small molecule 50 mg

Indications

No indication recorded.